The major P-450IIIA gene family member present in human liver is HLp which, like its rat liver orthologue P-450p, is inducible by glucocorticoids and catalyzes erythromycin N-demethylation. To develop a practical method to estimate the amounts of HLp in patients [14C]N-methyl erythromycin was injected into rats that had been pretreated with dexamethasone or with inducers of other forms of cytochrome P-450. The rate of demethylation of this substrate, measured simply as 14CO2 in the breath, correlated well with the concentrations of immunoreactive P-450p protein (r = 0.70), holocytochrome P-450p (r = 0.70), or with erythromycin N-demethylase activity (r = 0.90) determined in the liver microsomes prepared from each rat. Next, [14C]N-methyl erythromycin was administered to 30 patients and there was a sixfold interindividual variation in breath 14CO2 production seemingly unrelated to medications, smoking status or age. However, the average breath test values were twofold greater in female as compared to male patients (P less than 0.01). Breath 14CO2 production rose in patients retested after treatment with the P-450IIIA inducers dexamethasone (P less than 0.05) or rifampicin (P less than 0.05) and was decreased after treatment with the HLp inhibitor triacetyloleandomycin (P less than 0.05). We conclude that the erythromycin breath test provides a convenient assay of P-450IIIA cytochromes in rats and in some patients.
P B Watkins, S A Murray, L G Winkelman, D M Heuman, S A Wrighton, P S Guzelian
Title and authors | Publication | Year |
---|---|---|
Acceleration of infectious disease drug discovery and development using a humanized model of drug metabolism.
MacLeod AK, Coquelin KS, Huertas L, Simeons FRC, Riley J, Casado P, Guijarro L, Casanueva R, Frame L, Pinto EG, Ferguson L, Duncan C, Mutter N, Shishikura Y, Henderson CJ, Cebrian D, Wolf CR, Read KD |
Proceedings of the National Academy of Sciences | 2024 |
Impact of sex and pregnancy on hepatic CYP3A4 expression and activity in a humanized mouse model
Fashe MM, Miner TA, Collazo VL, Grieco JT, Fallon JK, Jackson KD, Lee CR |
Drug Metabolism and Disposition | 2024 |
Age-related modifications in CYP-dependent drug metabolism: role of stress.
Konstandi M, Johnson EO |
Frontiers in Endocrinology | 2023 |
Venous Thromboembolism and Primary Thromboprophylaxis in Perioperative Pancreatic Cancer Care.
Willems RAL, Michiels N, Lanting VR, Bouwense S, van den Broek BLJ, Graus M, Klok FA, Groot Koerkamp B, de Laat B, Roest M, Wilmink JW, van Es N, Mieog JSD, Ten Cate H, de Vos-Geelen J |
Cancers | 2023 |
Novel Approaches to Characterize Individual Drug Metabolism and Advance Precision Medicine.
Jackson KD, Achour B, Lee J, Geffert RM, Beers JL, Latham BD |
Drug metabolism and disposition: the biological fate of chemicals | 2023 |
Induction of CYP3A activity by dexamethasone may not be strong, even at high doses: insights from a case of tacrolimus co-administration.
Ohno Y, Oriyama T, Honda A, Kurokawa M, Takada T |
Journal of Pharmaceutical Health Care and Sciences | 2023 |
Nuclear Receptor PXR in Drug-Induced Hypercholesterolemia
M Karpale, J Hukkanen, J Hakkola |
Cells | 2022 |
Dexamethasone is a dose-dependent perpetrator of drug-drug interactions: implications for use in people living with HIV.
Jacobs TG, Marzolini C, Back DJ, Burger DM |
The Journal of antimicrobial chemotherapy | 2022 |
Effect of Rifampicin on the Pharmacokinetics of Evogliptin in Healthy Volunteers.
Shin Y, Choi C, Oh ES, Kim CO, Park K, Park MS |
Drug design, development and therapy | 2022 |
Breath Biomarkers in Diagnostic Applications
YL Pham, J Beauchamp |
Molecules (Basel, Switzerland) | 2021 |
Potential Dexamethasone–Direct Oral Anticoagulant Drug Interaction: Is This a Concern in COVID?
MA Smythe, C Burns, Q Liu, CL Garwood |
The Annals of pharmacotherapy | 2021 |
Effect of dexamethasone on direct Xa-inhibitor oral anticoagulant plasma levels in patients with COVID-19
FT Bosch, M Candeloro, N Potere, E Porreca, MD Nisio, PW Kamphuisen |
Thrombosis Research | 2021 |
Population Pharmacokinetics of Oxycodone and Metabolites in Patients with Cancer-Related Pain
BC Agema, AW Oosten, SD Sassen, WJ Rietdijk, CC van der Rijt, BC Koch, RH Mathijssen, SL Koolen |
Cancers | 2021 |
Induced volatolomics of pathologies
F Djago, J Lange, P Poinot |
Nature Reviews Chemistry | 2021 |
Induced volatolomics of pathologies.
Djago F, Lange J, Poinot P |
Nature Reviews Chemistry | 2021 |
Inhibition and induction of CYP enzymes in humans: an update
J Hakkola, J Hukkanen, M Turpeinen, O Pelkonen |
Archives of Toxicology | 2020 |
Erlotinib treatment induces cytochrome P450 3A activity in non‐small cell lung cancer patients
A Svedberg, S Vikingsson, A Vikström, N Hornstra, M Kentson, E Branden, H Koyi, B Bergman, H Gréen |
British Journal of Clinical Pharmacology | 2019 |
Perspectives from the Innovation and Quality Consortium Induction Working Group on Factors Impacting Clinical Drug-Drug Interactions Resulting from Induction: Focus on Cytochrome 3A Substrates
D Ramsden, C Fung, N Hariparsad, JR Kenny, M Mohutsky, NJ Parrott, S Robertson, DJ Tweedie |
Drug Metabolism and Disposition | 2019 |
Inhibitory Effect of Polypodium Leucotomos Extract on Cytochrome P450 3A-mediated Midazolam Metabolism
Y GOMI, Y NISHIMURA, N KURATA, M IWASE, K SHINYA, Y KIUCHI |
The Showa University Journal of Medical Sciences | 2019 |
Evaluation of 4β-Hydroxycholesterol and 25-Hydroxycholesterol as Endogenous Biomarkers of CYP3A4: Study with CYP3A-Humanized Mice
S Nitta, M Hashimoto, Y Kazuki, S Takehara, H Suzuki, M Oshimura, H Akita, K Chiba, K Kobayashi |
The AAPS Journal | 2018 |
Liver regeneration — mechanisms and models to clinical application
SJ Forbes, PN Newsome |
Nature Reviews Gastroenterology & Hepatology | 2016 |
Prediction of Gestational Age-Dependent Induction of In Vivo Hepatic CYP3A Activity Based on HepaRG Cells and Human Hepatocytes
Z Zhang, M Farooq, B Prasad, S Grepper, JD Unadkat |
Drug metabolism and disposition: the biological fate of chemicals | 2015 |
Comprehensive Physiology
SN Cheuvront, RW Kenefick |
Comprehensive Physiology | 2014 |
Precursors for cytochrome P450 profiling breath tests from an in silico screening approach
S Grafenstein, JE Fuchs, MM Huber, A Bassi, A Lacetera, V Ruzsanyi, J Troppmair, A Amann, KR Liedl |
Journal of Breath Research | 2014 |
Pharmacokinetic and Pharmacodynamic Drug Interactions with Ethanol (Alcohol)
LN Chan, GD Anderson |
Clinical Pharmacokinetics | 2014 |
The role of CYP3A4 in the biotransformation of bile acids and therapeutic implication for cholestasis
Jiezhong Chen, Kong-Nan Zhao, Chen Chen |
Annals of translational medicine | 2014 |
Pharmacokinetic considerations in chronic kidney disease and patients requiring dialysis
TJ Velenosi, BL Urquhart |
Expert Opinion on Drug Metabolism & Toxicology | 2014 |
The role of CYP3A4 in the biotransformation of bile acids and therapeutic implication for cholestasis
Jiezhong Chen, Kong-Nan Zhao, Chen Chen |
Annals of translational medicine | 2014 |
Organic anion transporting polypeptide 1B transporters modulate hydroxyurea pharmacokinetics
AL Walker, CS Lancaster, D Finkelstein, RE Ware, A Sparreboom |
American journal of physiology. Cell physiology | 2013 |
Breath Tests to Phenotype Drug Disposition in Oncology
FL Opdam, AS Modak, H Gelderblom, HJ Guchelaar |
Clinical Pharmacokinetics | 2013 |
Functional elements associated with hepatic regeneration in living donors after right hepatic lobectomy
GT Everson, JC Hoefs, CU Niemann, KM Olthoff, R Dupuis, S Lauriski, A Herman, N Milne, BW Gillespie, NP Goodrich, JE Everhart |
Liver Transplantation | 2013 |
OATP1B1 Polymorphism as a Determinant of Erythromycin Disposition
CS Lancaster, GH Bruun, CJ Peer, TS Mikkelsen, TJ Corydon, AA Gibson, S Hu, SJ Orwick, RH Mathijssen, WD Figg, SD Baker, A Sparreboom |
Clinical Pharmacology & Therapeutics | 2012 |
Phenotyping drug disposition in oncology
FL Opdam, H Gelderblom, HJ Guchelaar |
Cancer Treatment Reviews | 2012 |
Gender differences in pharmacokinetics of lumefantrine and its metabolite desbutyl-lumefantrine in rats : GENDER DIFFERENCES IN PK OF LUMEFANTRINE
SP Singh, GK Jain |
Biopharmaceutics & Drug Disposition | 2012 |
Pharmacokinetics and Pharmacodynamic Changes Associated with Aging and Implications for Drug Therapy
LC Sera, ML McPherson |
Clinics in Geriatric Medicine | 2012 |
Induction of cytochrome P450 enzymes: a view on human in vivo findings
J Hukkanen |
Expert Review of Clinical Pharmacology | 2012 |
The Handbook of Metabolomics
TW Fan, AN Lane, RM Higashi |
2012 | |
Progress Curve Mechanistic Modeling Approach for Assessing Time-Dependent Inhibition of CYP3A4
HJ Burt, H Pertinez, C Säll, C Collins, R Hyland, JB Houston, A Galetin |
Drug Metabolism and Disposition | 2012 |
Effect of ABCC2 (MRP2) Transport Function on Erythromycin Metabolism
RM Franke, CS Lancaster, CJ Peer, AA Gibson, AM Kosloske, SJ Orwick, RH Mathijssen, WD Figg, SD Baker, A Sparreboom |
Clinical Pharmacology & Therapeutics | 2011 |
The use of 13C-erythromycin as an in vivo probe to evaluate CYP3A-mediated drug interactions in rats
E Sugiyama, A Kikuchi, M Inada, H Sato |
Journal of Pharmaceutical Sciences | 2011 |
Direct radiocarbon analysis of exhaled air
T Schulze-König, L Wacker, HA Synal |
Journal of Analytical Atomic Spectrometry | 2011 |
Docetaxel pharmacokinetics and its correlation with two in vivo probes for cytochrome P450 enzymes: the C14-erythromycin breath test and the antipyrine clearance test
M Michael, C Cullinane, A Hatzimihalis, C O’Kane, A Milner, R Booth, S Schlicht, SJ Clarke, P Francis |
Cancer Chemotherapy and Pharmacology | 2011 |
In Vivo Inhibition of CYP3A-Mediated Midazolam Metabolism by Anchusan in Rats
Y Saito, Y Nishimura, N Kurata, M Iwase, K Aoki, H Yasuhara |
Journal of Pharmacological Sciences | 2011 |
Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects
SE Shoaf, P Bricmont, S Mallikaarjun |
British Journal of Clinical Pharmacology | 2011 |
Double-blind crossover study to assess potential differences in cytochrome P450 3A4 activity in healthy subjects receiving ondansetron plus dexamethasone, with and without aprepitant
SA Stoch, C Gargano, J Valentine, MP Braun, MG Murphy, M Fedgchin, A Majumdar, E Pequignot, KM Gottesdiener, KJ Petty, D Panebianco, D Dean, WK Kraft, HE Greenberg |
Cancer Chemotherapy and Pharmacology | 2010 |
Using drug probes to monitor hepatic drug metabolism in critically ill patients: midazolam, a flawed but useful tool for clinical investigation of CYP3A activity?
C Kirwan, I MacPhee, B Philips |
Expert Opinion on Drug Metabolism & Toxicology | 2010 |
A highly sensitive SPE- liquid/liquid extraction – RPLC analytical method for the determination of 6β-hydroxycortisol and cortisol in cancer patients' urine
Z Hong, F Yu, L Ying, L Aibin |
Journal of Medical Colleges of PLA | 2010 |
Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids
Z Dvorak, P Pavek |
Drug Metabolism Reviews | 2010 |
Human liver mitochondrial cytochrome P450 2D6--individual variations and implications in drug metabolism
MC Sangar, HK Anandatheerthavarada, W Tang, SK Prabu, MV Martin, M Dostalek, FP Guengerich, NG Avadhani |
The FEBS journal | 2009 |
Challenges for drug studies in children: CYP3A phenotyping as example
SN de Wildt, S Ito, G Koren |
Drug Discovery Today | 2009 |
Safety testing of metabolites: Expectations and outcomes
KS Pang |
Chemico-Biological Interactions | 2009 |
The Drug Transporter−Metabolism Alliance: Uncovering and Defining the Interplay
LZ Benet |
Molecular Pharmaceutics | 2009 |
PXR: a xenobiotic receptor of diverse function implicated in pharmacogenetics
B Zhang, W Xie, MD Krasowski |
Pharmacogenomics | 2008 |
Reply
J Bommer, T Heinrich, H Heidt, V Hafner, E Jenetzky, I Walter-Sack, G Mikus |
Nephrology Dialysis Transplantation | 2008 |
Inhibition and induction of human cytochrome P450 enzymes: current status
O Pelkonen, M Turpeinen, J Hakkola, P Honkakoski, J Hukkanen, H Raunio |
Archives of Toxicology | 2008 |
Examining sex-related differences in enteric itraconazole metabolism in healthy adults using grapefruit juice
PO Gubbins, BJ Gurley, DK Williams, SR Penzak, SA McConnell, AM Franks, M Saccente |
European Journal of Clinical Pharmacology | 2008 |
Influence of Solute Carriers on the Pharmacokinetics of CYP3A4 Probes
RM Franke, SD Baker, RH Mathijssen, EG Schuetz, A Sparreboom |
Clinical Pharmacology & Therapeutics | 2008 |
A multi-centre dose-escalation and pharmacokinetic study of diflomotecan in patients with advanced malignancy
JS Graham, S Falk, LM Samuel, JM Cendros, TR Evans |
Cancer Chemotherapy and Pharmacology | 2008 |
In vitro hepatic conversion of the anticancer agent nemorubicin to its active metabolite PNU-159682 in mice, rats and dogs: A comparison with human liver microsomes
L Quintieri, M Fantin, P Palatini, SD Martin, A Rosato, M Caruso, C Geroni, M Floreani |
Biochemical Pharmacology | 2008 |
The Influence of CYP3A5 Genotype on Dexamethasone Induction of CYP3A Activity in African Americans
PJ Roberts, KD Rollins, AD Kashuba, MF Paine, AC Nelsen, EE Williams, C Moran, JK Lamba, EG Schuetz, RL Hawke |
Drug Metabolism and Disposition | 2008 |
Forkhead Box A2–Mediated Regulation of Female-Predominant Expression of the Mouse Cyp2b9 Gene
T Hashita, T Sakuma, M Akada, A Nakajima, H Yamahara, S Ito, H Takesako, N Nemoto |
Drug Metabolism and Disposition | 2008 |
Synergism of Glucocorticoid Hormone with Growth Hormone for Female-Specific Mouse Cyp3a44 Gene Expression
T Sakuma, W Bhadhprasit, T Hashita, N Nemoto |
Drug Metabolism and Disposition | 2008 |
Novel Single Nucleotide Polymorphisms in the Promoter and Intron 1 of Human Pregnane X Receptor/NR1I2 and Their Association with CYP3A4 Expression
J Lamba, V Lamba, S Strom, R Venkataramanan, E Schuetz |
Drug Metabolism and Disposition | 2007 |
Cytochrome P4503Apolymorphisms and immunosuppressive drugs: an update
D Anglicheau, C Legendre, P Beaune, E Thervet |
Pharmacogenomics | 2007 |
Effects of Uptake and Efflux Transporter Inhibition on Erythromycin Breath Test Results
LA Frassetto, S Poon, C Tsourounis, C Valera, LZ Benet |
Clinical Pharmacology & Therapeutics | 2007 |
Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma
R Chugh, T Wagner, KA Griffith, JM Taylor, DG Thomas, FP Worden, KM Leu, MM Zalupski, LH Baker |
Cancer | 2007 |
Sex-dependent genetic markers of CYP3A4 expression and activity in human liver microsomes
M Schirmer, A Rosenberger, K Klein, B Kulle, MR Toliat, P Nürnberg, UM Zanger, L Wojnowski |
Pharmacogenomics | 2007 |
In vivoEffect of I'm-Yunity™ on Hepatic Cytochrome P450 3A4
JP Nicandro, C Tsourounis, L Frassetto, BJ Guglielmo |
Journal of Herbal Pharmacotherapy | 2007 |
Side Effects of Drugs Annual
T Vial, J Descotes, F Braun, M Behrend |
Side Effects of Drugs Annual | 2007 |
Cytochrome P450 Expression and Regulation in CYP3A4/CYP2D6 Double Transgenic Humanized Mice
MA Felmlee, HK Lon, FJ Gonzalez, AM Yu |
Drug Metabolism and Disposition | 2007 |
Cytochrome P450 4F subfamily: At the crossroads of eicosanoid and drug metabolism
A Kalsotra, HW Strobel |
Pharmacology & Therapeutics | 2006 |
Effect of widely used combinations of antiretroviral therapy on liver CYP3A4 activity in HIV-infected patients
S Mouly, N Rizzo-Padoin, G Simoneau, C Verstuyft, G Aymard, C Salvat, I Mahé, JF Bergmann |
British Journal of Clinical Pharmacology | 2006 |
Evidence for cytochrome P450 3A expression and catalytic activity in rat blood lymphocytes
A Dey, S Yadav, A Dhawan, PK Seth, D Parmar |
Life Sciences | 2006 |
The Influence of Granisetron on the Pharmacokinetics and Pharmacodynamics of Docetaxel in Asian Lung Cancer Patients
M Miyata, K Yasuda, N Burioka, H Takane, H Suyama, Y Shigeoka, M Endo, J Kurai, M Morita, T Igishi, E Shimizu |
The Cancer Journal | 2006 |
Genotyping and phenotyping cytochrome P450: Perspectives for cancer treatment
RH Mathijssen, RH van Schaik |
European Journal of Cancer | 2006 |
Paediatric Clinical Pharmacology
T Johnson |
Paediatric Clinical Pharmacology: A Subtle Compromise | 2006 |
Noninvasive Evaluation of Liver Disease Severity
JC Hoefs, PT Chen, P Lizotte |
Clinics in Liver Disease | 2006 |
Role of Protein Kinase C-mediated Protein Phosphorylation in Mitochondrial Translocation of Mouse CYP1A1, Which Contains a Non-canonical Targeting Signal
VR Dasari, HK Anandatheerthavarada, MA Robin, E Boopathi, G Biswas, JK Fang, DW Nebert, NG Avadhani |
The Journal of biological chemistry | 2006 |
Growth Hormone Regulation of Sex-Dependent Liver Gene Expression
DJ Waxman, C OConnor |
Molecular Endocrinology | 2006 |
Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor
J Chen, K Raymond |
Annals of clinical microbiology and antimicrobials | 2006 |
Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4
S Zhou, E Chan, X Li, M Huang |
Therapeutics and Clinical Risk Management | 2005 |
Effect of Chronic Administration of Ritonavir on Function of Cytochrome P450 3A and P-Glycoprotein in Rats
M Kageyama, H Namiki, H Fukushima, S Terasaka, T Togawa, A Tanaka, Y Ito, N Shibata, K Takada |
Biological & Pharmaceutical Bulletin | 2005 |
Gender Differences in the Pharmacokinetics of Oral Dermatologic Medications
DJ Fife, HI Maibach |
Cutaneous and Ocular Toxicology | 2005 |
Measurement of hepatic functional mass by means of 13C-methacetin and 13C-phenylalanine breath tests in chronic liver disease: comparison with Child-Pugh score and serum bile acid levels
D Festi, S Capodicasa, L Sandri, L Colaiocco-Ferrante, T Staniscia, E Vitacolonna, A Vestito, P Simoni, G Mazzella, P Portincasa, E Roda, A Colecchia |
World journal of gastroenterology : WJG | 2005 |
Measurement of hepatic functional mass by means of 13C-methacetin and 13C-phenylalanine breath tests in chronic liver disease: Comparison with Child-Pugh score and serum bile acid levels
D Festi |
World journal of gastroenterology : WJG | 2005 |
Mechanism-Based Inhibition of Cytochrome P450 3A4 by Therapeutic Drugs:
S Zhou, SY Chan, BC Goh, E Chan, W Duan, M Huang, HL McLeod |
Clinical Pharmacokinetics | 2005 |
Cytochrome P450
PR de Montellano |
Cytochrome P450 | 2005 |
METABOLISM-BASED DRUG-DRUG INTERACTIONS: WHAT DETERMINES INDIVIDUAL VARIABILITY IN CYTOCHROME P450 INDUCTION?
C Tang, JH Lin, AY Lu |
Drug Metabolism and Disposition | 2005 |
Growth Hormone Determines Sexual Dimorphism of Hepatic Cytochrome P450 3A4 Expression in Transgenic Mice
C Cheung, AM Yu, CS Chen, KW Krausz, LG Byrd, L Feigenbaum, RJ Edwards, DJ Waxman, FJ Gonzalez |
The Journal of pharmacology and experimental therapeutics | 2005 |
Population pharmacokinetics of weekly docetaxel in patients with advanced cancer
KA Slaviero, SJ Clarke, AJ McLachlan, EY Blair, LP Rivory |
British Journal of Clinical Pharmacology | 2004 |
Suppression of female-specific murine Cyp2b9 gene expression by growth or glucocorticoid hormones
T Sakuma, K Kitajima, M Nishiyama, M Mashino, T Hashita, N Nemoto |
Biochemical and Biophysical Research Communications | 2004 |
Within-person variability of urinary 6β-hydroxycortisol to urinaryl ratios in Caucasian women
Z Chen, LA Dunning, KE Anderson, JL Holtzman, W Zheng |
Steroids | 2004 |
Collaborated regulation of female-specific murine Cyp3a41 gene expression by growth and glucocorticoid hormones
T Sakuma, K Kitajima, M Nishiyama, Y Endo, K Miyauchi, K Jarukamjorn, N Nemoto |
Biochemical and Biophysical Research Communications | 2004 |
Effects of growth hormone deficiency and rhGH replacement therapy on the 6?-hydroxycortisol/free cortisol ratio, a marker of CYP3A activity, in growth hormone-deficient children
B Sinu�s, E Mayayo, A Fanlo, E Mayayo, ML Bernal, P Bocos, E Bello, JI Labarta, A Ferr�ndez-Long�s |
European Journal of Clinical Pharmacology | 2004 |
Ethnic Differences in Genetic Polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1
S OZAWA, A SOYAMA, M SAEKI, H FUKUSHIMA-UESAKA, M ITODA, S KOYANO, K SAI, Y OHNO, Y SAITO, J SAWADA |
Drug Metabolism and Pharmacokinetics | 2004 |
Prediction of Irinotecan Pharmacokinetics by Use of Cytochrome P450 3A4 Phenotyping Probes
RH Mathijssen, FA de Jong, RH van Schaik, ER Lepper, LE Friberg, T Rietveld, P Bruijn, WJ Graveland, WD Figg, J Verweij, A Sparreboom |
JNCI Journal of the National Cancer Institute | 2004 |
The Effects of Modifying In Vivo Cytochrome P450 3A (CYP3A) Activity on Etoricoxib Pharmacokinetics and of Etoricoxib Administration on CYP3A Activity
NG Agrawal, CZ Matthews, RS Mazenko, EJ Woolf, AG Porras, X Chen, JL Miller, N Michiels, M Wehling, A Schultz, AB Gottlieb, WK Kraft, HE Greenberg, SA Waldman, SP Curtis, KM Gottesdiener |
The Journal of Clinical Pharmacology | 2004 |
Principles of Gender-Specific Medicine
G Supinski, LA Callahan |
Principles of Gender-Specific Medicine | 2004 |
Influence of intravenous methylprednisolone pulse treatment on the disposition of ciclosporin and hepatic CYP3A activity in rats
H Konishi, M Sumi, T Minouchi, A Yamaji, M Sumi, N Shibata, K Takada |
Journal of Pharmacy and Pharmacology | 2004 |
Advanced Methods of Pharmacokinetic and Pharmacodynamic Systems Analysis Volume 3
DZ DArgenio |
2004 | |
Aging Biology and Geriatric Clinical Pharmacology
AJ McLean, DG Couteur |
Pharmacological reviews | 2004 |
The Metabolism of Pyrazoloacridine (NSC 366140) by Cytochromes P450 and Flavin Monooxygenase in Human Liver Microsomes
JM Reid, DL Walker, JK Miller, LM Benson, AJ Tomlinson, S Naylor, AL Blajeski, PM LoRusso, MM Ames |
Clinical cancer research | 2004 |
Cytochrome P450 3A and their regulation
O Burk, L Wojnowski |
Naunyn-Schmiedeberg's Archives of Pharmacology | 2004 |
Effects of growth hormone deficiency and rhGH replacement therapy on the 6?-hydroxycortisol/free cortisol ratio, a marker of CYP3A activity, in growth hormone-deficient children
B Sinus, E Mayayo, A Fanlo, E Mayayo, ML Bernal, P Bocos, E Bello, JI Labarta, A Ferrndez-Longs |
European Journal of Clinical Pharmacology | 2004 |
Phenotyping CYP3A using midazolam in cancer and noncancer Asian patients
HS Lee, BC Goh, L Fan, YM Khoo, L Wang, R Lim, AB Ong, C Chua |
British Journal of Clinical Pharmacology | 2003 |
Genotype???phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women
MD Floyd, G Gervasini, AL Masica, G Mayo, AL George, K Bhat, RB Kim, GR Wilkinson |
Pharmacogenetics | 2003 |
Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy
KA Slaviero, SJ Clarke, LP Rivory |
The Lancet Oncology | 2003 |
Two CCAAT/enhancer binding protein sites in the cytochrome P4503A1 locus. Potencial role in the glucocorticoid response
E Rodrigues, MJ Vilarem, V Ribeiro, P Maurel, MC Lechner |
European Journal of Biochemistry | 2003 |
Gender-Specific Implications for Cardiovascular Medication Use in the Elderly
JB Schwartz |
Cardiology in Review | 2003 |
Sex is a major determinant of CYP3A4 expression in human liver
R Wolbold, K Klein, O Burk, AK Nüssler, P Neuhaus, M Eichelbaum, M Schwab, UM Zanger |
Hepatology | 2003 |
Cytochrome P450 3A4 activity after surgical stress
CE Haas, DC Kaufman, CE Jones, AH Burstein, W Reiss |
Critical Care Medicine | 2003 |
The [14C-N-methyl]-erythromycin breath test dosimetry complies with the French regulations for radiation safety
C Salvat, S Mouly, N Rizzo-Padoin, AL Knellwolf, G Simoneau, M Duet, V Nataf, O Bailliart, JF Bergmann |
Fundamental & Clinical Pharmacology | 2003 |
Single-point plasma or urine dextromethorphan method for determining CYP3A activity
BP Kuo, OY Hu, CH Hsiong, LH Pao, TS Chen, CF Hung |
Biopharmaceutics & Drug Disposition | 2003 |
An inter- and intra-laboratory comparison of breath13CO2analysis
F Perri, RM Zagari, JS Uebersax, M Quitadamo, F Bazzoli |
Alimentary Pharmacology & Therapeutics | 2003 |
Drugs and the Pharmaceutical Sciences
D Thompson |
Drugs and the Pharmaceutical Sciences | 2003 |
In vivo activation of the human CYP3A4 promoter in mouse liver and regulation by pregnane X receptors
W Zhang, A Purchio, K Chen, SM Burns, CH Contag, PR Contag |
Biochemical Pharmacology | 2003 |
Drug Metabolizing Enzymes: Cytochrome P450 and Other Enzymes in Drug Discovery and Development
K Bachmann, S Wrighton, B Ring |
Drug Metabolizing Enzymes: Cytochrome P450 and Other Enzymes in Drug Discovery and Development | 2003 |
Quinine 3-hydroxylation as a biomarker reaction for the activity of CYP3A4 in man
RA Mirghani, Ö Ericsson, G Tybring, LL Gustafsson, L Bertilsson |
European Journal of Clinical Pharmacology | 2003 |
Measurement of hepatic and intestinal CYP3A4 and PGP activity by combined po + iv [ 14 C]erythromycin breath and urine test
WP Lemahieu, BD Maes, Y Ghoos, P Rutgeerts, K Verbeke, Y Vanrenterghem |
AJP Gastrointestinal and Liver Physiology | 2003 |
The Influence of Sex on Pharmacokinetics:
JB Schwartz |
Clinical Pharmacokinetics | 2003 |
Strategies and Molecular Probes to Investigate the Role of Cytochrome P450 in Drug Metabolism: Focus On In Vitro Studies
MT Donato, JV Castell |
Clinical Pharmacokinetics | 2003 |
Troglitazone Induces CYP3A4 Activity Leading to Falsely Abnormal Dexamethasone Suppression Test
EV Dimaraki, CA Jaffe |
The Journal of clinical endocrinology and metabolism | 2003 |
MODELING OF INTESTINAL DRUG ABSORPTION: ROLES OF TRANSPORTERS AND METABOLIC ENZYMES (FOR THE GILLETTE REVIEW SERIES)
KS Pang |
Drug Metabolism and Disposition | 2003 |
A TRANSGENIC MOUSE MODEL WITH A LUCIFERASE REPORTER FOR STUDYING IN VIVO TRANSCRIPTIONAL REGULATION OF THE HUMAN CYP3A4 GENE
W Zhang, AF Purchio, K Chen, J Wu, L Lu, R Coffee, PR Contag, DB West |
Drug Metabolism and Disposition | 2003 |
PHARMACOKINETICS OF CITALOPRAM IN RELATION TO GENETIC POLYMORPHISM OF CYP2C19
BN Yu, GL Chen, N He, DS Ouyang, XP Chen, ZQ Liu, HH Zhou |
Drug Metabolism and Disposition | 2003 |
Transgenic Mouse Models of Human CYP3A4 Gene Regulation
GR Robertson, J Field, B Goodwin, S Bierach, M Tran, A Lehnert, C Liddle |
Molecular pharmacology | 2003 |
Urinary 6?-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals
MM Galteau, F Shamsa |
European Journal of Clinical Pharmacology | 2003 |
Growth hormone secretion pattern is an independent regulator of growth hormone actions in humans
CA Jaffe, DK Turgeon, K Lown, R Demott-Friberg, PB Watkins |
American journal of physiology. Endocrinology and metabolism | 2002 |
Breath testing for human liver function assessment
A Armuzzi, M Candelli, MA Zocco, A Andreoli, AD Lorenzo, EC Nista, L Miele, F Cremonini, IA Cazzato, A Grieco, G Gasbarrini, A Gasbarrini |
Alimentary Pharmacology & Therapeutics | 2002 |
Is quinine a suitable probe to assess the hepatic drug-metabolizing enzyme CYP3A4?
S Wanwimolruk, MF Paine, SN Pusek, PB Watkins |
British Journal of Clinical Pharmacology | 2002 |
Sex and age differences in the pharmacokinetics of alosetron
KM Koch, JL Palmer, N Noordin, JJ Tomlinson, C Baidoo |
British Journal of Clinical Pharmacology | 2002 |
REGULATION OFCYP3AGENETRANSCRIPTION BY THEPREGNANEX RECEPTOR*
B Goodwin, MR Redinbo, SA Kliewer |
Annual Review of Pharmacology and Toxicology | 2002 |
Identification of the novel splicing variants for the hPXR in human livers
S Fukuen, T Fukuda, H Matsuda, A Sumida, I Yamamoto, T Inaba, J Azuma |
Biochemical and Biophysical Research Communications | 2002 |
The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer
AB Spurdle, B Goodwin, E Hodgson, JL Hopper, X Chen, DM Purdie, MR McCredie, GG Giles, G Chenevix-Trench, C Liddle |
Pharmacogenetics | 2002 |
A Wide Interindividual Variability of Urinary 6β-Hydroxycortisol to Free Cortisol in 487 Healthy Japanese Subjects in Near Basal Condition
K Inagaki, M Inagaki, T Kataoka, I Sekido, MA Gill, M Nishida |
Therapeutic Drug Monitoring | 2002 |
The interaction of medications used in palliative care
SA Bernard |
Hematology/Oncology Clinics of North America | 2002 |
Application of Isotopic Ratio Mass Spectrometry for the in Vitro Determination of Demethylation Activity in Human Liver Microsomes Using N-methyl-13C-Labeled Substrates
F Grand, I Kilinc, A Sarkis, J Guitton |
Analytical Biochemistry | 2002 |
Receptor-dependent transcriptional activation of cytochrome P4503A genes: induction mechanisms, species differences and interindividual variation in man
GG Gibson, NJ Plant, KE Swales, A Ayrton, W El-Sankary |
Xenobiotica | 2002 |
Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response
LP Rivory, KA Slaviero, SJ Clarke |
British Journal of Cancer | 2002 |
Explaining Interindividual Variability of Docetaxel Pharmacokinetics and Pharmacodynamics in Asians Through Phenotyping and Genotyping Strategies
BC Goh, SC Lee, LZ Wang, L Fan, JY Guo, J Lamba, E Schuetz, R Lim, HL Lim, AB Ong, HS Lee |
Journal of Clinical Oncology | 2002 |
Genotyping and Phenotyping the Cytochrome P-450 Enzymes:
KA Bachmann |
American Journal of Therapeutics | 2002 |
The Nuclear Pregnane X Receptor: A Key Regulator of Xenobiotic Metabolism
SA Kliewer, B Goodwin, TM Willson |
Endocrine reviews | 2002 |
The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants
J Zhang, P Kuehl, ED Green, JW Touchman, PB Watkins, A Daly, SD Hall, P Maurel, M Relling, C Brimer, K Yasuda, SA Wrighton, M Hancock, RB Kim, S Strom, K Thummel, CG Russell, JR Hudson, EG Schuetz, MS Boguski |
Pharmacogenetics | 2001 |
Pharmacokinetic interaction between mefloquine and ritonavir in healthy volunteers
Y Khaliq, K Gallicano, C Tisdale, G Carignan, C Cooper, A McCarthy |
British Journal of Clinical Pharmacology | 2001 |
Evolutionarily divergent electron donor proteins interact with P450MT2 through the same helical domain but different contact points
HK Anandatheerthavarada, G Amuthan, G Biswas, MA Robin, R Murali, MR Waterman, NG Avadhani |
The EMBO Journal | 2001 |
Active secretion and enterocytic drug metabolism barriers to drug absorption1PII of original article: S0169-409X(96)003304. The article was originally published in Advanced Drug Delivery Reviews 20 (1996) 99–112.1
VJ Wacher, L Salphati, LZ Benet |
Advanced Drug Delivery Reviews | 2001 |
Effect of influenza immunization on CYP3A4 activity
MS Hayney, RJ Hammes, JP Fine, JA Bianco |
Vaccine | 2001 |
Effects of Metronidazole on Hepatic CYP3A4 Activity
CE Haas, DC Kaufman, RC DiCenzo |
Pharmacotherapy | 2001 |
Race but Not Age Affects Erythromycin Breath Test Results in Older Hypertensive Men
JB Schwartz |
The Journal of Clinical Pharmacology | 2001 |
Assessment of drug-drug interactions: concepts and approaches
RJ Weaver |
Xenobiotica | 2001 |
SEX AND ETHNICITY MAY CHIEFLY INFLUENCE THE INTERACTION OF FLUCONAZOLE WITH CALCINEURIN INHIBITORS12:
AS Mathis, T DiRenzo, GS Friedman, B Kaplan, R Adamson |
Transplantation | 2001 |
The Erythromycin Breath Test For the Prediction of Drug Clearance:
LP Rivory, KA Slaviero, JM Hoskins, SJ Clarke |
Clinical Pharmacokinetics | 2001 |
Mdr1 Limits CYP3A Metabolism in Vivo
LB Lan, JT Dalton, EG Schuetz |
Molecular pharmacology | 2000 |
Quantitative RT-PCR for CYP3A4 mRNA in human peripheral lymphocytes: induction of CYP3A4 in lymphocytes and in liver by rifampicin
T Nakamoto, I Hase, S Imaoka, T Hiroi, Y Oda, A Asada, Y Funae |
Pharmacogenetics | 2000 |
Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes
DS Streetman, JS Bertino, AN Nafziger |
Pharmacogenetics | 2000 |
Variability in Activity of Hepatic CYP3A4 in Patients Infected with HIV
D Slain, A Pakyz, DS Israel, S Monroe, RE Polk |
Pharmacotherapy | 2000 |
Differential alteration of cytochrome P450 isoenzymes in two experimental models of cirrhosis
MC Bastien, F Leblond, V Pichette, JP Villeneuve |
Canadian Journal of Physiology and Pharmacology | 2000 |
Can oral midazolam predict oral cyclosporine disposition?
MF Paine, CL Davis, DD Shen, CL Marsh, VA Raisys, KE Thummel |
European Journal of Pharmaceutical Sciences | 2000 |
Gender-Specific Effects on Verapamil Pharmacokinetics and Pharmacodynamics in Humans
ME Krecic-Shepard, CR Barnas, J Slimko, MP Jones, JB Schwartz |
The Journal of Clinical Pharmacology | 2000 |
Expression and induction of CYP1A1/1A2, CYP2A6 and CYP3A4 in primary cultures of human hepatocytes: a 10-year follow-up
V Meunier, M Bourrie, B Julian, E Marti, F Guillou, Y Berger, G Fabre |
Xenobiotica | 2000 |
Correlation Between Docetaxel Clearance and Estimated Cytochrome P450 Activity by Urinary Metabolite of Exogenous Cortisol
N Yamamoto, T Tamura, Y Kamiya, I Sekine, H Kunitoh, N Saijo |
Journal of Clinical Oncology | 2000 |
Pediatric Acute Lymphoblastic Leukemia: Challenges and Controversies in 2000
CA Felix, BJ Lange, JM Chessells |
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program | 2000 |
Low Intraindividual Variability of Cyclosporin A Exposure Reduces Chronic Rejection Incidence and Health Care Costs
BD Kahan, M Welsh, DL Urbauer, MB Mosheim, KM Beusterien, MR Wood, LP Schoenberg, J Dicesare, SM Katz, CT Buren |
Journal of the American Society of Nephrology : JASN | 2000 |
Route-dependent metabolism of morphine in the vascularly perfused rat small intestine preparation
M M Doherty, K S Pang |
Pharmaceutical Research | 2000 |
Effects of a chargrilled meat diet on expression of CYP3A, CYP1A, and P-glycoprotein levels in healthy volunteers
RJ Fontana, KS Lown, MF Paine, L Fortlage, RM Santella, JS Felton, MG Knize, A Greenberg, PB Watkins |
Gastroenterology | 1999 |
Effects of Chronic Administration of Glucocorticoid on Midazolam Pharmacokinetics in Humans
M Nakajima, T Suzuki, T Sasaki, T Yokoi, A Hosoyamada, T Yamamoto, Y Kuroiwa |
Therapeutic Drug Monitoring | 1999 |
Rifampicin Treatment Greatly Increases the Apparent Oral Clearance of Qninidine
P Damkier, LL Hansen, K Brøsen |
Pharmacology & Toxicology | 1999 |
Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine
P Damkier, LL Hansen, K Brosen |
British Journal of Clinical Pharmacology | 1999 |
Correlation Between Pretransplantation Test Dose Cyclosporine Pharmacokinetic Profiles and Posttransplantation Sirolimus Blood Levels in Renal Transplant Recipients
B Kaplan, HU Meier-Kriesche, KL Napoli, BD Kahan |
Therapeutic Drug Monitoring | 1999 |
Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A*
MT Kinirons, D O'Shea, RB Kim, JD Groopman, KE Thummel, AJ Wood, GR Wilkinson |
Clinical Pharmacology & Therapeutics | 1999 |
Concurrent Administration of the Erythromycin Breath Test (EBT) and Oral Midazolam as In Vivo Probes for CYP3A Activity
J McCrea, T Prueksaritanont, BJ Gertz, A Carides, L Gillen, S Antonello, MJ Brucker, C Miller-Stein, B Osborne, S Waldman |
The Journal of Clinical Pharmacology | 1999 |
Effects of Rifampin on Tacrolimus Pharmacokinetics in Healthy Volunteers
MF Hebert, RM Fisher, CL Marsh, D Dressler, I Bekersky |
The Journal of Clinical Pharmacology | 1999 |
Physiological Role of the N-terminal Processed P4501A1 Targeted to Mitochondria in Erythromycin Metabolism and Reversal of Erythromycin-mediated Inhibition of Mitochondrial Protein Synthesis
HK Anandatheerthavarada, C Vijayasarathy, SV Bhagwat, G Biswas, J Mullick, NG Avadhani |
The Journal of biological chemistry | 1999 |
Lidocaine and monoethylglycinexylidide serum determinations to analyze liver function of cirrhotic patients after oral administration
A E Muñoz, C Miguez, M Rubio, M Bartellini, D Levi, A Podestá, V Niselman, R Terg |
Digestive Diseases and Sciences | 1999 |
Cytochrome P450 3A: Ontogeny and Drug Disposition
SN de Wildt, GL Kearns, JS Leeder, JN van den Anker |
Clinical Pharmacokinetics | 1999 |
Effects of CYP3A Inhibition on the Metabolism of Cilostazol:
A Suri, WP Forbes, SL Bramer |
Clinical Pharmacokinetics | 1999 |
Cytochrome P450 enzymes and drug metabolism--basic concepts and methods of assessment
P Glue, R P Clement |
Cellular and Molecular Neurobiology | 1999 |
Clinical importance of non-genetic and genetic cytochrome P450 function tests in liver disease
E Tanaka |
Journal of Clinical Pharmacy and Therapeutics | 1998 |
Effect of CYP3A inhibition on vesnarinone metabolism in humans*
C Wandel, CC Lang, DC Cowart, AF Girard, S Bramer, DA Flockhart, AJ Wood |
Clinical Pharmacology & Therapeutics | 1998 |
The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin*
JC Gorski, DR Jones, BD Haehner-Daniels, MA Hamman, EM O'Mara, SD Hall |
Clinical Pharmacology & Therapeutics | 1998 |
IN VITRO AND IN VIVO DRUG INTERACTIONS INVOLVING HUMAN CYP3A
KE Thummel, GR Wilkinson |
Annual Review of Pharmacology and Toxicology | 1998 |
Gut wall metabolism of verapamil in older people: effects of rifampicin-mediated enzyme induction
MF Fromm, K Dilger, D Busse, HK Kroemer, M Eichelbaum, U Klotz |
British Journal of Clinical Pharmacology | 1998 |
SXR, a novel steroid and xenobiotic-sensing nuclear receptor
B Blumberg, W Sabbagh, H Juguilon, J Bolado, CM van Meter, ES Ong, RM Evans |
Genes & development | 1998 |
A qualitative method for assessing the14C labelling position in [14C]-dimethyl aminoantipyrine (aminopyrine)
P Levêque, B Gallez |
Journal of Labelled Compounds and Radiopharmaceuticals | 1998 |
Disposition of 14C-eptifibatide after intravenous administration to healthy men
KB Alton, T Kosoglou, S Baker, MB Affrime, MN Cayen, JE Patrick |
Clinical Therapeutics | 1998 |
Quantification of 3-month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam*
AD Kashuba, JS Bertino, ML Rocci, RW Kulawy, DJ Beck, AN Nafziger |
Clinical Pharmacology & Therapeutics | 1998 |
Selective effects of somatostatin analogs on human drug-metabolizing enzymes*
E Rasmussen, B Eriksson, K Öberg, U Bondesson, A Rane |
Clinical Pharmacology & Therapeutics | 1998 |
Respective Roles of Human Cytochrome P-4502E1, 1A2, and 3A4 in the Hepatic Microsomal Ethanol Oxidizing System
KS Salmela, IG Kessova, IB Tsyrlov, CS Lieber |
Alcoholism, clinical and experimental research | 1998 |
Effects of glucocorticoids on pharmacokinetics and pharmacodynamics of midazolam in rats
M Watanabe, T Tateishi, M Asoh, H Nakura, M Tanaka, T Kumai, S Kobayashi |
Life Sciences | 1998 |
HumanMDR1and Mousemdr1aP-Glycoprotein Alter the Cellular Retention and Disposition of Erythromycin, but Not of Retinoic Acid or Benzo(a)pyrene
EG Schuetz, K Yasuda, K Arimori, JD Schuetz |
Archives of Biochemistry and Biophysics | 1998 |
Effect of Multiple Doses of Rifampin on the [ 14 C N -methyl] Erythromycin Breath Test in Healthy Male Volunteers
MN Gharaibeh, LP Gillen, B Osborne, JI Schwartz, SA Waldman |
The Journal of Clinical Pharmacology | 1998 |
Cytochromes P450 in crustacea
MO James, SM Boyle |
Comparative Biochemistry and Physiology Part C: Pharmacology, Toxicology and Endocrinology | 1998 |
Identification of cytochrome P450 isozymes involved in metabolism of the α 1 -adrenoceptor blocker tamsulosin in human liver microsomes
H KAMIMURA, S OISHIOE, H MATSUSHIMA, T WATANABE, S HIGUCHI, M HALL, SG Wood, LF Chasseaud |
Xenobiotica | 1998 |
Metabolic capacities in cultured human hepatocytes obtained by a new isolating procedure from non-wedge small liver biopsies
P David, C Viollon, E Alexandre, A Azimzadeh, L Nicod, P Wolf, D Jaeck, K Boudjema, L Richert |
Human & Experimental Toxicology | 1998 |
Environmental Xenobiotics and the Antihormones Cyproterone Acetate and Spironolactone Use the Nuclear Hormone Pregnenolone X Receptor to Activate the CYP3A23 Hormone Response Element
EG Schuetz, C Brimer, JD Schuetz |
Molecular pharmacology | 1998 |
Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression
KS Lown, DG Bailey, RJ Fontana, SK Janardan, CH Adair, LA Fortlage, MB Brown, W Guo, PB Watkins |
Journal of Clinical Investigation | 1997 |
Dietary salt increases first-pass elimination of oral quinidine*
D Darbar, S Dell'Orto, K Mörike, GR Wilkinson, DM Roden |
Clinical Pharmacology & Therapeutics | 1997 |
Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery
M Hebert |
Advanced Drug Delivery Reviews | 1997 |
Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine*
KS Lown, RR Mayo, AB Leichtman, H Hsiao, DK Turgeon, P Schmiedlin-Ren, MB Brown, W Guo, SJ Rossi, LZ Benet, PB Watkins |
Clinical Pharmacology & Therapeutics | 1997 |
Assessment of Cytochrome P450 3A4 Activity during the Menstrual Cycle Using Alfentanil as a Noninvasive Probe
ED Kharasch, M Russell, K Garton, G Lentz, TA Bowdle, K Cox |
Anesthesiology | 1997 |
Metabolism of rifabutin in human enterocyte and liver microsomes: Kinetic parameters, identification of enzyme systems, and drug interactions with macrolides and antifungal agents*
E Iatsimirskaia, S Tulebaev, E Storozhuk, I Utkin, D Smith, N Gerber, T Koudriakova |
Clinical Pharmacology & Therapeutics | 1997 |
Predicting Drug Interactions In Vivo from Experiments In Vitro
CA Jamis-Dow, ML Pearl, PB Watkins, DS Blake, RW Klecker, JM Collins |
American Journal of Clinical Oncology | 1997 |
Steady-state pharmacokinetics of delavirdine in HIV-positive patients: Effect on erythromycin breath test *
CL Cheng, DE Smith, PL Carver, SR Cox, PB Watkins, DS Blake, CA Kauffman, KM Meyer, GL Amidon, PL Stetson |
Clinical Pharmacology & Therapeutics | 1997 |
Localization of Multiple Forms of Inducible Cytochromes P450 in Rat Liver Mitochondria: Immunological Characteristics and Patterns of Xenobiotic Substrate Metabolism
HK Anandatheerthavarada, S Addya, RS Dwivedi, G Biswas, J Mullick, NG Avadhani |
Archives of Biochemistry and Biophysics | 1997 |
Use of Probe Drugs as Predictors of Drug Metabolism in Humans
KT Kivistö, HK Kroemer |
The Journal of Clinical Pharmacology | 1997 |
In vitro analysis of the activity of the major human hepatic CYP enzyme (CYP3A4) using [N-methyl-14C]-erythromycin
RJ Riley, D Howbrook |
Journal of Pharmacological and Toxicological Methods | 1997 |
Do Endogenous Volatile Organic Chemicals Measured in Breath Reflect and Maintain CYP2E1 Levelsin Vivo?
JM Mathews, JH Raymer, AS Etheridge, GR Velez, JR Bucher |
Toxicology and Applied Pharmacology | 1997 |
Genetic Polymorphisms in Human Drug-Metabolizing Enzymes: Potential Uses of Reverse Genetics to Identify Genes of Toxicological Relevance
A Puga, DW Nebert, RA McKinnon, AG Menon |
Critical Reviews in Toxicology | 1997 |
Rifampicin and isoniazid increase acetaminophen and isoniazid cytotoxicity in human HepG2 hepatoma cells
L Nicod, C Viollon, A Regnier, A Jacqueson, L Richert |
Human & Experimental Toxicology | 1997 |
Xenobiotic-induced hepatotoxicity: mechanisms of liver injury and methods of monitoring hepatic function
MG Sturgill, GH Lambert |
Clinical chemistry | 1997 |
Assessment of monoethylglycinexylidide as measure of liver function for patients with chronic viral hepatitis
RJ Elin, MW Fried, M Sampson, M Ruddel, DE Kleiner, AM DiBisceglie |
Clinical chemistry | 1997 |
Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency
MW Linder, RA Prough, R Valdes |
Clinical chemistry | 1997 |
Pharmacokinetic Optimisation of Cancer Chemotherapy: Effect on Outcomes
E Masson, WC Zamboni |
Clinical Pharmacokinetics | 1997 |
Erythromycin Breath Test and Clinical Transplantation
PB Watkins |
Therapeutic Drug Monitoring | 1996 |
Active secretion and enterocytic drug metabolism barriers to drug absorption
VJ Wacher, L Salphati, LZ Benet |
Advanced Drug Delivery Reviews | 1996 |
Erythromycin-felodipine interaction: Magnitude, mechanism, and comparison with grapefruit juice*
DG Bailey, JR Bend, JM Arnold, LT Tran, JD Spence |
Clinical Pharmacology & Therapeutics | 1996 |
Rifampin drastically reduces plasma concentrations and effects of oral midazolam
JT Backman, KT Olkkola, PJ Neuvonen |
Clinical Pharmacology & Therapeutics | 1996 |
Comparison of the dapsone recovery ratio and the erythromycin breath test as in vivo probes of CYP3A activity in patients with rheumatoid arthritis receiving cyclosporine*
CM Stein, MT Kinirons, T Pincus, GR Wilkinson, AJ Wood |
Clinical Pharmacology & Therapeutics | 1996 |
P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans
EG Schuetz, AH Schinkel, MV Relling, JD Schuetz |
Proceedings of the National Academy of Sciences | 1996 |
Influence of clinicopathological variables on CYP protein expression in human liver
J George, K Byth, GC Farrell |
Journal of Gastroenterology and Hepatology | 1996 |
Use of Hepatic Lidocaine Metabolism to Monitor Patients with Chronic Liver Disease
ML Shiffman, VA Luketic, AJ Sanyal, EB Thompson |
Therapeutic Drug Monitoring | 1996 |
Psychiatry, psychopharmacology and P-450s
P Glue, C Banfield |
Human Psychopharmacology: Clinical and Experimental | 1996 |
The use of lidocaine as a test of liver function in liver transplantation
JM Potter, M Oellerich |
Liver Transplantation and Surgery | 1996 |
Identification of Human Liver Cytochrome P-450 3A4 as the Enzyme Responsible for Fentanyl and Sufentanil N-Dealkylation
T Tateishi, Y Krivoruk, YF Ueng, AJ Wood, FP Guengerich, M Wood |
Anesthesia & Analgesia | 1996 |
The influence of cytochrome P450 enzyme activity on the composition and quantity of volatile organics in expired breath
JM Mathews, JH Raymer, GR Velez, CE Garner, JR Bucher |
Biomarkers | 1996 |
The effects of menopause and hormone replacement therapies on prednisolone and erythromycin pharmacokinetics*
RZ Harris, SM Tsunoda, P Mroczkowski, H Wong, LZ Benet |
Clinical Pharmacology & Therapeutics | 1996 |
Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N-demethylation*
DR Jones, JC Gorski, BD Haehner, EM O'Mara, SD Hall |
Clinical Pharmacology & Therapeutics | 1996 |
Quantification of dextromethorphan and metabolites: a dual phenotypic marker for cytochrome P450 3A4/5 and 2D6 activity
DR Jones, JC Gorski, MA Hamman, SD Hall |
Journal of Chromatography B: Biomedical Sciences and Applications | 1996 |
Trimethadione as a probe drug to estimate hepatic oxidizing capacity in humans
E Tanaka, A Ishikawa, M Abei, S Kobayashi |
Comparative Biochemistry and Physiology Part C: Pharmacology, Toxicology and Endocrinology | 1996 |
Dextromethorphan as an in vivo probe for the simultaneous determination of CYP2D6 and CYP3A activity
J Ducharme, S Abdullah, IW Wainer |
Journal of Chromatography B Biomedical Sciences and Applications | 1996 |
Assessment of Doxylamine Influence on Mixed Function Oxidase Activity upon Multiple Dose Oral Administration to Normal Volunteers
GA Thompson, JV st. Peter, MA Heise, ZD Horowitz, GC Salyers, TT Charles, C Brezovic, DA Russell, JA Skare, JH Powell |
Journal of Pharmaceutical Sciences | 1996 |
Identification of Human Liver Cytochrome P-450 3A4 as the Enzyme Responsible for Fentanyl and Sufentanil N-Dealkylation:
T Tateishi, Y Krivoruk, YF Ueng, AJ Wood, FP Guengerich, M Wood |
Anesthesia & Analgesia | 1996 |
Introduction to Drug Metabolism
GG Gibson, P Skett |
1996 | |
The Use of Therapeutic Drug Monitoring to Optimise Immunosuppressive Therapy:
SM Tsunoda, FT Aweeka |
Clinical Pharmacokinetics | 1996 |
Drug Interactions and the Cytochrome P-450 Enzymes
JA Carlston |
Pediatric Asthma, Allergy & Immunology | 1995 |
Omeprazole does not affect measured CYP3A4 activity using the erythromycin breath test
T Tateishi, SG Graham, Y Krivoruk, AJ Wood |
British Journal of Clinical Pharmacology | 1995 |
Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease
J George, M Murray, K Byth, GC Farrell |
Hepatology | 1995 |
Age but not gender selectively affects expression of individual cytochrome P450 proteins in human liver
J George |
Biochemical Pharmacology | 1995 |
The erythromycin breath test predicts the clearance of midazolam*
KS Lown, KE Thummel, PE Benedict, DD Shen, DK Turgeon, S Berent, PB Watkins |
Clinical Pharmacology & Therapeutics | 1995 |
Alternative cyclosporine metabolic pathways and toxicity
U Christians, KF Sewing |
Clinical Biochemistry | 1995 |
Omeprazole does not affect measured CYP3A4 activity using the erythromycin breath test [letter]
T Tateishi, SG Graham, Y Krivoruk, AJ Wood |
British Journal of Clinical Pharmacology | 1995 |
The influence of rifampin treatment on caffeine clearance in healthy man
H Wietholtz, T Zysset, HU Marschall, K Generet, S Matern |
Journal of Hepatology | 1995 |
The Use of In Vitro Metabolism Techniques in the Planning and Interpretation of Drug Safety Studies
SA Wrighton, BJ Ring, M Vandenbranden |
Toxicologic pathology | 1995 |
GENETIC PREDISPOSITION TO DRUG-INDUCED LIVER DISEASE
RJ Fontana, PB Watkins |
Gastroenterology Clinics of North America | 1995 |
Evaluation of the intestinal absorption of erythromycin in man: absolute bioavailability and comparison with enteric coated erythromycin
A A Somogyi, F Bochner, D Hetzel, D B Williams |
Pharmaceutical Research | 1995 |
Hepatic lidocaine metabolism and liver histology in patients with chronic hepatitis and cirrhosis
ML Shiffman, VA Luketic, AJ Sanyal, PF Duckworth, PP Purdum, MJ Contos, AS Mills, LE Edinboro, A Poklis |
Hepatology | 1994 |
Catalytic selectivity of human cytochrome P450 enzymes: relevance to drug metabolism and toxicity
FP Guengerich |
Toxicology Letters | 1994 |
Importance of cytochrome P-450IIIA activity in determining dosage and blood levels of FK 506 and cyclosporine in liver transplant recipients
Y Cakaloglu, JM Tredger, J Devlin, R Williams |
Hepatology | 1994 |
Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily
JC Gorski, SD Hall, DR Jones, M VandenBranden |
Biochemical Pharmacology | 1994 |
Characterization of dextromethorphan N-demethylation by human liver microsomes
JC Gorski, DR Jones, SA Wrighton, SD Hall |
Biochemical Pharmacology | 1994 |
Role of Human Cytochromes P450 in the Metabolic Activation of Chemical Carcinogens and Toxins
FJ Gonzalez, HV Gelboin |
Drug Metabolism Reviews | 1994 |
Pharmacokinetic Evaluation of a New Oral Cyclosporine Formulation
JK Whipple, KS Lewis, SD Weitman, RK Ausman, DW Bourne, W Andrews, MB Adams, EA Sasse, EJ Quebbeman |
Pharmacotherapy | 1994 |
Augmented arterial pressure responses to cyclosporine in spontaneously hypertensive rats. Role of cytochrome P-450 3A
AK Basu, S Ghosh, PK Mohanty, CO Watlington |
Hypertension | 1994 |
Pharmacokinetics of Drugs
PG Welling, LP Balant |
1994 | |
Assessment of the Use of Single Cytochrome P450 Enzymes in Drug Research
MR Waterman, M Hildebrand |
1994 | |
Pharmacogenetic Phenotyping and Genotyping: Present Status and Future Potential
FJ Gonzalez, JR Idle |
Clinical Pharmacokinetics | 1994 |
Assessment of Liver Metabolic Function: Clinical Implications
J Brockmöller, I Roots |
Clinical Pharmacokinetics | 1994 |
Human cytochrome P450 3A4: enzymatic properties of a purified recombinant fusion protein containing NADPH-P450 reductase
MS Shet, CW Fisher, PL Holmans, RW Estabrook |
Proceedings of the National Academy of Sciences | 1993 |
Regulation of human liver cytochromes P-450 in family 3A in primary and continuous culture of human hepatocytes
EG Schuetz, JD Schuetz, SC Strom, MT Thompson, RA Fisher, DT Molowa, D Li, PS Guzelian |
Hepatology | 1993 |
Cyclosporin metabolism in transplant patients
U Christians, KF Sewing |
Pharmacology & Therapeutics | 1993 |
Interferon suppresses erythromycin metabolism in rats and human subjects
PI Craig, M Tapner, GC Farrell |
Hepatology | 1993 |
Cultured adult rat jejunal explants as a model for studying regulation of CYP3A
P Schmiedlin-Ren, PE Benedict, WO Dobbins, M Ghosh, JC Kolars, PB Watkins |
Biochemical Pharmacology | 1993 |
Validation and use of cloned, expressed human drug-metabolizing enzymes in heterologous cells for analysis of drug metabolism and drug-drug interactions
RP Remmel, B Burchell |
Biochemical Pharmacology | 1993 |
The use of in vitro metabolism studies in the understanding of new drugs
SH Chiu |
Journal of Pharmacological and Toxicological Methods | 1993 |
Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes
JC Kolars, P Schmiedlin-Ren, JD Schuetz, C Fang, PB Watkins |
Journal of Clinical Investigation | 1992 |
Human cytochrome P-450 enzymes
FP Guengerich |
Life Sciences | 1992 |
Immunoquantification of cytochrome P-450 3A on rat paraffin-embedded liver tissue
Y Horsmans, M Stevens, A Geubel, C Harvengt, J Rahier |
Liver | 1992 |
Enzyme induction by drugs and toxins
AM Batt, G Siest, J Magdalou, MM Galteau |
Clinica Chimica Acta | 1992 |
Human cytochromes P450: problems and prospects
FJ Gonzalez |
Trends in Pharmacological Sciences | 1992 |
Absence of CYP3 A Genetic Polymorphism Assessed by Urinary Excretion of 6 β-Hydroxycortisol in 102 Healthy Subjects on Rifampicin
Y Horsmans, JP Desager, C Harvengt |
Pharmacology & Toxicology | 1992 |
Effect of age and gender on the activity of human hepatic CYP3A
CM Hunt, WR Westerkam, GM Stave |
Biochemical Pharmacology | 1992 |
The Human Hepatic Cytochromes P450 Involved in Drug Metabolism
SA Wrighton, JC Stevens |
Critical Reviews in Toxicology | 1992 |
Heterogeneity of cytochrome P450IIIA expression in rat gut epithelia
JC Kolars, P Schmiedlin-Ren, WO Dobbins, J Schuetz, SA Wrighton, PB Watkins |
Gastroenterology | 1992 |
Hepatic cytochrome P-4503A (CYP3A) activity in the elderly
CM Hunt, WR Westerkam, GM Stave, JA Wilson |
Mechanisms of Ageing and Development | 1992 |
DRUG METABOLISM BY CYTOCHROMES P450 IN THE LIVER AND SMALL BOWEL
PB Watkins |
Gastroenterology Clinics of North America | 1992 |
P450 Enzymes: Inhibition Mechanisms, Genetic Regulation and Effects of Liver Disease
M Murray |
Clinical Pharmacokinetics | 1992 |
The functioning liver mass
G Molino |
La Ricerca in Clinica e in Laboratorio | 1991 |
Role of human hepatic cytochromes P450 in drug metabolism and toxicity
J George, GC Farrell |
Australian and New Zealand Journal of Medicine | 1991 |
Utilization of labeled Escherichia coli as phospholipase substrate
P Elsbach, J Weiss |
Methods in enzymology | 1991 |
Prediction of Xenobiotic Metabolism by Non-Invasive Methods
S Loft, HE Poulsen |
Pharmacology & Toxicology | 1990 |
Differential regulation of liver P-450III cytochromes in choline-deficient rats: Implications for the erythromycin breath test as a parameter of liver function
JC Kolars, SA Murray, KM Peters, PB Watkins |
Hepatology | 1990 |
Metabolism of 17 α-ethynylestradiol in humans
FP Guengerich |
Life Sciences | 1990 |
Expression of cytochrome P-450 enzymes in cultured human hepatocytes
F MOREL, PH BEAUNE, D RATANASAVANH, JP FLINOIS, CS YANG, FP GUENGERICH, A GUILLOUZO |
European Journal of Biochemistry | 1990 |
Substrate specificities and functions of the P450 cytochromes
MR Juchau |
Life Sciences | 1990 |
The role of cytochromes P-450 in cyclosporine metabolism
PB Watkins |
Journal of the American Academy of Dermatology | 1990 |
Distribution of cytochromes P-450, cytochrome b5, and nadph-cytochrome P-450 reductase in an entire human liver
PB Watkins, SA Murray, PE Thomas, SA Wrighton |
Biochemical Pharmacology | 1990 |
Hormonal Regulation of Male-specific Rat Hepatic Cytochrome P-450g (P-450IIC13) by Androgens and the Pituitary
PD McClellan-Green, P Linko, HN Yeowell, JA Goldstein |
The Journal of biological chemistry | 1989 |